Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › gefitinib

gefitinib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of gefitinib

34 trials tracked of gefitinib: 11 in phase 3 or 4 and 1 with published results. The most-cited published study has 120 citations.

34Trials tracked
11Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 8 Phase 2 22 Other / NA 1
  1. Phase 3 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Completed · 120 cited
  2. Phase 4 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed
  3. Phase 4 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Completed
  4. Phase 4 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed
  5. Phase 3 Iressa Follow-up Trial Completed
  6. Phase 3 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed
Show 28 more trials
  1. Phase 3 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed
  2. Phase 3 A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer Completed
  3. Phase 3 First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia Completed
  4. Phase 3 Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients Completed
  5. Phase 3 A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone Completed
  6. Phase 2 Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
  7. Phase 2 First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Completed
  8. Phase 2 Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene Completed
  9. Phase 2 Phase II Iressa & Carbo/Gem in NSCLC Completed
  10. Phase 2 Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer Completed
  11. Phase 2 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Completed
  12. Phase 2 Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Completed
  13. Phase 2 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) Completed
  14. Phase 2 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed
  15. Phase 2 Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer Completed
  16. Phase 2 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
  17. Phase 2 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed
  18. Phase 2 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Completed
  19. Phase 2 Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers Completed
  20. Phase 2 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed
  21. Phase 2 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone Completed
  22. Phase 2 A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Completed
  23. Phase 2 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed
  24. Phase 2 Iressa Study in Patients With Salivary Gland Cancer Completed
  25. Phase 2 A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment Completed
  26. Phase 2 Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Completed
  27. Phase 2 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) Completed
  28. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
Oncology RCT
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases Rezivertinib shows longer brain metastasis control than gefitinib in lung cancer trial
A phase III randomized controlled trial in 159 treatment-naïve patients with EGFR-mutated NSCLC and baseline CNS metastases found rezivertin…
Rezivertinib kept brain cancer growth in lung cancer patients under control for nearly two years longer than gefitinib in a major trial.
Apr 4, 2026